Corcept Therapeutics Sets Sights on $1 Billion Revenue Mark as Demand for Hypercortisolism Medications Soars
The first quarter of 2026 was a record-breaker for Corcept Therapeutics, with the company raking in $164.9 million in revenue, a substantial increase from the $157.2 million reported in the prior year period. This growth has prompted the company to revise its 2026 revenue guidance upwards, projecting sales of between $950 million and $1.05 billion.
At the heart of this success is Corcept's Endocrinology Division, which continues to see a surge in demand for its medications. According to President Sean Maduck, the division ended the first quarter with a record number of new prescriptions written from a record number of prescribers, resulting in an all-time high for the number of patients receiving these treatments.
One of the key drivers behind this growth is the increasing awareness among physicians of the importance of screening and treating hypercortisolism. The landmark results of Corcept's CATALYST and MOMENTUM trials have provided consistent, complementary evidence that this condition is a major underlying cause of many patients' difficult-to-treat diabetes and hypertension.
The CATALYST trial showed that 24% of patients with resistant diabetes had hypercortisolism, and that treatment with Korlym led to substantial reductions in hemoglobin A1c, weight, and weight circumference compared to placebo. These findings were published in the prominent journal Diabetes Care in December 2025 and referenced in the March 2026 American Association of Clinical Endocrinology (ACE) guidance document for the management of diabetes.
The MOMENTUM study, meanwhile, revealed that 27% of patients with resistant hypertension had hypercortisolism. These results were featured in an oral presentation at the annual conference of the American College of Cardiology (ACC) last month.
Corcept's new specialty pharmacy vendor has also played a crucial role in this success story, expertly onboarding thousands of patients transferred from the company's former vendor and ensuring that they receive the medication they've been prescribed. While there is still some work to be done in terms of clearing the insurance prior authorization backlog accumulated during this transition, Maduck remains confident that demand for Corcept's medications will continue to soar as physicians adapt their practices in response to these landmark findings.
As medical practices evolve and more patients are screened for and treated for hypercortisolism, the number of patients receiving Corcept's medications is expected to increase substantially. With its revenue guidance revised upwards and a growing pipeline of clinical trials underway, Corcept Therapeutics is well-positioned to reach its ambitious goal of $1 billion in revenue by the end of 2026.
